RLMD - Rasio kapitalisasi pasar marang pendapatan Relmada Corp
The normalized P/S of Relmada Therapeutics (RLMD) reflects the business valuation trend, with the parameter reaching . Relmada Therapeutics integrates ESG principles by adhering to bioethical testing standards and laboratory environmental sustainability. Patent protection for its unique antidepressants enables premium pricing power. Vast market potential and the completion of clinical stages guarantee high future demand for this innovative therapy.
Rincian metrik lan analitis perusahaan Relmada (RLMD)
- nilai saham lan prakiraan konsensus rega:
- statistik kapitalisasi pasar:
- indikator kapitalisasi buku:
- rincian struktur utang lan likuiditas bisnis:
Utang marang Modal Relmada Therapeutics|RLMD - Utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal Relmada Corp|RLMD - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku Relmada|RLMD - Utang jangka dawa perusahaan|Kewajiban jangka cendhak Relmada Therapeutics|Likuiditas darurat relmada.com
- statistik bathi lan rasio pasar:
RLMD - Penghasilan resik|Proyeksi bathi mangsa ngarep Relmada Therapeutics|RLMD - Koefisien rega marang bathi|Rasio kapitalisasi marang bathi mangsa ngarep Relmada Therapeutics Inc|RLMD - Pangali PEG|Rasio total nilai perusahaan marang bathi operasional sadurunge panyusutan Relmada|RLMD - Bathi operasional EBITDA|Bathi resik saben saham sajrone 12 wulan pungkasan Relmada Therapeutics|RLMD - Bathi saben saham sajrone rolas wulan pungkasan|Owah-owahan bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan relmada.com|RLMD - Wutah bathi saben saham ing taun lumaku|Dinamika bathi saben saham sing diarepake ing taun ngarep Relmada Therapeutics
- rincian pendapatan lan dodolan emiten:
Analisis umum perusahaan:RLMD relmada.com
The valuation of Relmada Therapeutics (RLMD) depends directly on the outcomes of the REL-1017 trials and the drug's safety profile. The historical P/S ratio illustrates the market capitalization relative to current sales volumes. The current value of reflects the proportion between the share price and revenue, measuring the degree of premium paid for future success. Sharp fluctuations in this ratio signal shifting investor expectations regarding the product's commercialization.
Pesaing Relmada Therapeutics
Multiplikator P/S biogen.com (BIIB)|Neurocrine Biosciences, Inc. - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan RGC|AXSM: Kapitalisasi marang pendapatan|ACADIA Corp - Kapitalisasi marang volume dodolan|XENE: Multiplikator P/S|vikingtherapeutics.com - Rasio kapitalisasi pasar marang pendapatan|SUPN (Supernus) - Multiplikator P/S|Rega marang dodolan Catalyst Pharma CPRX|Rasio rega marang pendapatan Denali Therapeutics Inc (DNLI)|HRMY (Harmony Corp) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S BHVN (Biohaven Ltd.)|Multiplikator P/S amylyx.com AMLX|TRVI - Rasio rega marang pendapatan|Rasio rega marang dodolan PRAX|AVXL: Multiplikator P/S|Rega marang dodolan CeriBell EEG (CBLL)|Kapitalisasi marang pendapatan PRTA|Multiplikator P/S Alector Therapeutics|Kapitalisasi marang pendapatan ANNX (Annexon)|Kapitalisasi marang volume dodolan OMER|Multiplikator P/S NGNE (Neurogene Corp)|Koefisien rega marang pendapatan AC Immune Inc (ACIU)|Voyager Therapeutics - Multiplikator P/S|neumoratx.com (NMRA) - Kapitalisasi marang pendapatan|Scilex (SCLX) - Rasio rega marang pendapatan|TVGN - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Alpha Cognition Inc|CGTX: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Inhibikase Therapeutics (IKT)|Rasio rega marang pendapatan SAVA (cassavasciences.com)|Rasio rega marang pendapatan Assertio ASRT|COYA - Kapitalisasi marang pendapatan|VistaGen Therapeutics Inc - Multiplikator P/S|OVID (Ovid Therapeutics Inc.) - Rasio kapitalisasi marang pendapatan|Acumen Pharmaceuticals (ABOS) - Rasio rega marang pendapatan|Rasio kapitalisasi marang pendapatan CRVO|ATHE (Alterity Therapeutics Ltd.) - Multiplikator P/S|Rega marang dodolan Clene Nanomedicine CLNN|Kapitalisasi marang pendapatan PEPG (PepGen Inc.)|Multiplikator P/S Jupiter Neurosciences, Inc. (JUNS)|Rasio rega marang pendapatan Annovis Bio, Inc. ANVS|Rasio kapitalisasi pasar marang pendapatan GRCE|AIFF - Rasio rega marang pendapatan|Rega marang dodolan Klotho Neurosciences Inc|neurosense-tx.com (NRSN) - Rasio rega marang pendapatan|Reviva Pharmaceuticals, Inc. - Rasio kapitalisasi pasar marang pendapatan|MTVA (MetaVia Inc.) - Multiplikator P/S|Rega marang dodolan neuraxis.com NRXS|Rasio rega marang pendapatan Helius Medical (HSDT)|Rasio rega marang pendapatan PASG (passagebio.com)|Rasio rega marang pendapatan Neuphoria Therapeutics NEUP|NERV - Kapitalisasi marang pendapatan|Athira Pharma, Inc. - Multiplikator P/S|ADXN - Multiplikator P/S|ALZN: Multiplikator P/S|Rasio kapitalisasi marang pendapatan CYCN|PTIX (Protagenic Therapeutics Inc.) - Multiplikator P/S|Multiplikator P/S Pasithea|Kapitalisasi marang pendapatan CRGT (Cortigent, Inc.)|ATXI (avenuetx.com) - Rasio kapitalisasi pasar marang pendapatan|BrainStorm Cell Therapeutics - Kapitalisasi marang pendapatan|Kapitalisasi marang volume dodolan CARA (Cara Therapeutics Inc.)|Chromocell Therapeutics Corporation - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan ELYM (Eliem Therapeutics)|ITCI: Multiplikator P/S|Rega marang dodolan longboardpharma.com (LBPH)|Rasio rega marang pendapatan Marinus Pharmaceuticals, Inc.|NKGN: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S NRBO|Multiplikator P/S Sage Therapeutics Inc (SAGE)|Rasio rega marang pendapatan Synaptogenix, Inc. SNPX|TRVN (trevena.com) - Rasio rega marang dodolan|Vigil Neuro - Multiplikator P/S|Rega marang dodolan anewmeds.com|CERE (Cerevel) - Kapitalisasi marang pendapatan
